首页 > 最新文献

Acta Clinica Belgica最新文献

英文 中文
Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium. 比利时加格列净治疗2型糖尿病患者糖尿病肾病的健康经济模型
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2021-12-27 DOI: 10.1080/17843286.2021.2015554
Winde Jorissen, Lieven Annemans, Nicolas Louis, Andreas Nilsson, Michael Willis

Objectives: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial showed reduced renal and cardiovascular (CV) events in patients with type 2 diabetes (T2D) and diabetic kidney disease (DKD) treated with canagliflozin 100 mg added to Standard of Care (SoC) versus SoC alone. This led to an extension of the canagliflozin 100 mg European marketing authorisation, making canagliflozin the first pharmacological therapy to receive authorisation for the treatment of DKD since the RENAAL and IDNT trials more than 20 years ago. Given the importance of cost-effectiveness analyses in health care, this study aimed to leverage the CREDENCE trial outcomes to estimate the cost-effectiveness of canagliflozin 100 mg from the perspective of the Belgian healthcare system.

Methods: A microsimulation model (CREDENCE Economic Model of DKD), developed using patient-level CREDENCE trial data, was leveraged to model the progression of DKD and CV outcomes, associated costs, and life quality. Unit costs and quality-adjusted life years (QALYs) were sourced from the literature. The time horizon was 10 years and sensitivity analyses were performed.

Results: Canagliflozin was associated with sizable gains in life-years and QALYs over 10 years, and the incremental cost-effectiveness ratio cost offsets associated with reductions in CV and renal complications resulted in overall net cost savings from the perspective of the Belgian healthcare system.

Conclusion: Model-based results suggest that adding canagliflozin 100 mg to SoC can improve outcomes for patients with DKD while reducing overall net costs for the Belgian healthcare system.

目的:卡格列净和肾脏事件在已建立的肾病临床评估(CREDENCE)试验中显示,与单独加用卡格列净100mg标准护理(SoC)相比,加用卡格列净治疗2型糖尿病(T2D)和糖尿病肾病(DKD)患者的肾脏和心血管(CV)事件减少。这导致canagliflozin 100mg欧洲上市许可的延长,使canagliflozin成为自20多年前RENAAL和IDNT试验以来首个获得DKD治疗许可的药物疗法。考虑到成本-效果分析在医疗保健中的重要性,本研究旨在利用CREDENCE试验结果,从比利时医疗保健系统的角度估计canagliflozin 100mg的成本-效果。方法:利用患者级CREDENCE试验数据开发的微观模拟模型(CREDENCE经济模型)来模拟DKD和CV结局的进展、相关成本和生活质量。单位成本和质量调整生命年(QALYs)来源于文献。时间跨度为10年,并进行敏感性分析。结果:从比利时医疗保健系统的角度来看,加格列净与10年以上生命年和质量年的可观收益相关,并且与CV和肾脏并发症减少相关的增量成本-效果比成本抵消导致总体净成本节约。结论:基于模型的结果表明,在SoC中添加100 mg canagliflozin可以改善DKD患者的预后,同时降低比利时医疗保健系统的总体净成本。
{"title":"Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium.","authors":"Winde Jorissen,&nbsp;Lieven Annemans,&nbsp;Nicolas Louis,&nbsp;Andreas Nilsson,&nbsp;Michael Willis","doi":"10.1080/17843286.2021.2015554","DOIUrl":"https://doi.org/10.1080/17843286.2021.2015554","url":null,"abstract":"<p><strong>Objectives: </strong>The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial showed reduced renal and cardiovascular (CV) events in patients with type 2 diabetes (T2D) and diabetic kidney disease (DKD) treated with canagliflozin 100 mg added to Standard of Care (SoC) versus SoC alone. This led to an extension of the canagliflozin 100 mg European marketing authorisation, making canagliflozin the first pharmacological therapy to receive authorisation for the treatment of DKD since the RENAAL and IDNT trials more than 20 years ago. Given the importance of cost-effectiveness analyses in health care, this study aimed to leverage the CREDENCE trial outcomes to estimate the cost-effectiveness of canagliflozin 100 mg from the perspective of the Belgian healthcare system.</p><p><strong>Methods: </strong>A microsimulation model (CREDENCE Economic Model of DKD), developed using patient-level CREDENCE trial data, was leveraged to model the progression of DKD and CV outcomes, associated costs, and life quality. Unit costs and quality-adjusted life years (QALYs) were sourced from the literature. The time horizon was 10 years and sensitivity analyses were performed.</p><p><strong>Results: </strong>Canagliflozin was associated with sizable gains in life-years and QALYs over 10 years, and the incremental cost-effectiveness ratio cost offsets associated with reductions in CV and renal complications resulted in overall net cost savings from the perspective of the Belgian healthcare system.</p><p><strong>Conclusion: </strong>Model-based results suggest that adding canagliflozin 100 mg to SoC can improve outcomes for patients with DKD while reducing overall net costs for the Belgian healthcare system.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39642299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Should I, can I, dare I? Patients' view on stopping long-term antidepressant use, a qualitative study. 我应该,我能,我敢吗?患者对停止长期使用抗抑郁药的看法:一项定性研究。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2022-01-10 DOI: 10.1080/17843286.2021.2024384
Ellen Van Leeuwen, Sibyl Anthierens, Mieke L van Driel, An De Sutter, Rani De Beir, Thierry Christiaens

Background and aim: The rise in long-term antidepressant use is concerning. Long-term antidepressant (AD) use, much longer than recommended by guidelines, can result in risk of adverse events and generate unnecessary costs. In order to mitigate these risks, patients views about their antidepressants and how to discontinue need to be taken into account. We aimed to explore patients' experiences and views of discontinuing long-term AD, barriers and facilitators of discontinuation and required support.

Methods: Semi-structured face to face interviews were conducted with 14 patients with long-term AD use in primary care. Interviews were analysed thematically.

Results: Participants describe various perceptions about discontinuation. There is fear of returning to their depression, even in those who were ambivalent about the effectiveness and safety of AD continuation. Participants describe low confidence in their own coping resources, fear of stress, and previous negative experiences with stopping. This enhances their perception of AD dependence. Participants indicate the importance of the support of their GP and their social network to help them withdraw.

Conclusion: Discontinuation of long-term antidepressants is a complex issue for patients. More awareness of the lack of evidence and the potential risks of long-term AD continuation is required. By raising the issue and offering support during discontinuation GPs can help their patients stop AD. A greater focus on non-pharmacological approaches of depression in primary care is needed to reduce unnecessary AD use.

背景与目的:长期抗抑郁药物使用的增加令人担忧。长期使用抗抑郁药(AD),远远超过指南建议的时间,可导致不良事件的风险,并产生不必要的费用。为了减轻这些风险,需要考虑患者对抗抑郁药的看法以及如何停用。我们的目的是探讨患者的经验和观点,停止长期阿尔茨海默病,障碍和促进停止和所需的支持。方法:对14例长期使用AD的初级保健患者进行半结构化面对面访谈。访谈按主题进行分析。结果:参与者描述了对停药的不同看法。即使是那些对阿尔茨海默病继续治疗的有效性和安全性持矛盾态度的人,也害怕回到抑郁状态。参与者描述了他们对自己的应对资源缺乏信心,对压力的恐惧,以及之前停止的负面经历。这增强了他们对AD依赖的感知。参与者表示,他们的全科医生和他们的社会网络的支持,以帮助他们退出的重要性。结论:长期抗抑郁药物的停药对患者来说是一个复杂的问题。需要更多地认识到证据的缺乏和长期AD持续的潜在风险。通过提出问题并在停药期间提供支持,全科医生可以帮助他们的患者停止AD。需要在初级保健中更多地关注抑郁症的非药物治疗方法,以减少不必要的阿尔茨海默病的使用。
{"title":"Should I, can I, dare I? Patients' view on stopping long-term antidepressant use, a qualitative study.","authors":"Ellen Van Leeuwen,&nbsp;Sibyl Anthierens,&nbsp;Mieke L van Driel,&nbsp;An De Sutter,&nbsp;Rani De Beir,&nbsp;Thierry Christiaens","doi":"10.1080/17843286.2021.2024384","DOIUrl":"https://doi.org/10.1080/17843286.2021.2024384","url":null,"abstract":"<p><strong>Background and aim: </strong>The rise in long-term antidepressant use is concerning. Long-term antidepressant (AD) use, much longer than recommended by guidelines, can result in risk of adverse events and generate unnecessary costs. In order to mitigate these risks, patients views about their antidepressants and how to discontinue need to be taken into account. We aimed to explore patients' experiences and views of discontinuing long-term AD, barriers and facilitators of discontinuation and required support.</p><p><strong>Methods: </strong>Semi-structured face to face interviews were conducted with 14 patients with long-term AD use in primary care. Interviews were analysed thematically.</p><p><strong>Results: </strong>Participants describe various perceptions about discontinuation. There is fear of returning to their depression, even in those who were ambivalent about the effectiveness and safety of AD continuation. Participants describe low confidence in their own coping resources, fear of stress, and previous negative experiences with stopping. This enhances their perception of AD dependence. Participants indicate the importance of the support of their GP and their social network to help them withdraw.</p><p><strong>Conclusion: </strong>Discontinuation of long-term antidepressants is a complex issue for patients. More awareness of the lack of evidence and the potential risks of long-term AD continuation is required. By raising the issue and offering support during discontinuation GPs can help their patients stop AD. A greater focus on non-pharmacological approaches of depression in primary care is needed to reduce unnecessary AD use.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39803459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The efficiency of the EmERGE pathway to provide continuity of care for medically stable people living with HIV in Belgium. 在比利时,EmERGE途径为医疗状况稳定的艾滋病毒感染者提供持续护理的效率。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2021-11-21 DOI: 10.1080/17843286.2021.2004697
Eduard J Beck, Sundhiya Mandalia, Platonas Yfantopoulos, Christopher I Jones, Stephen Bremner, Jennifer Whetham, Marie Wittevrongel, Ludwig Apers
The life-expectancy of people living with HIV (PLHIV) has increased due to the earlier and increased use of antiretroviral drugs (ARVs) [1]. The life-expectancy of PLHIV now approximates that of people not living with HIV [2]. Increased life-expectancy will increase the number of PLHIV including those aged 50 years or older [3]. NonHIV cancers, cardiovascular disease, and other noncommunicable diseases (NCDs) are the most common comorbidities in older PLHIV and the most common cause of death of PLHIV in high-income countries. These NCDs also are becoming more prevalent in lowand middle-income countries [4,5] and PLHIV will increasingly need to use HIV and non-HIV health and social services. As part of their HIV-response, many countries are monitoring and evaluating the use, cost, outcome and impact of health services for PLHIV and tracking them across sites [6], which can assist in developing more integrated and cost-effective health services [7]. Mobile Health (mHealth), or the use of wireless technology to deliver health services and information using mobile communication devices, such as mobile phones or other devices [8,9], plays an important role in linking and integrating health services. An increased use of mHealth has been seen in Belgium [10], the United States [11] and other countries as part of their respective responses to their 2020 COVID-19 epidemic. mHealth provides an increasingly important role to ensure continuity of medical and paramedical care in countries, including the management of acute and chronic diseases, such as cancer services [12]. The published studies on mHealth interventions, however, indicate the variable effectiveness of mHealth tools, for those that were HIV-specific [8,9,13] or mHealth tools for other chronic diseases [14,15]. Most of these studies were performed in high-income countries; however, mHealth is increasingly being used in lowand middle-income countries [16–21]. The Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and innovation to Generate Evidence for personalised care (EmERGE) Project co-designed, developed and implemented a new digital mHealth Pathway, including a mobile health application (App) [22]. This allowed for the electronic transfer of personal health information to people living with medically stable HIV and communication with their caregivers [12]. A recent review identified nine functions that an mHealth App ought to fulfil [9]. These functions covered many of the communication aspects, but two important aspects were missing: firstly, that data collected, transmitted, and stored at either end are protected in terms of their confidentiality and security (Table 1); secondly such technology needs to be affordable and efficient [23]. Most studies to date have not included the cost for developing, implementing, and supporting these mHealth Apps, let alone assess their cost-effectiveness or potential cost-savings that mHealth potentially pro
{"title":"The efficiency of the EmERGE pathway to provide continuity of care for medically stable people living with HIV in Belgium.","authors":"Eduard J Beck,&nbsp;Sundhiya Mandalia,&nbsp;Platonas Yfantopoulos,&nbsp;Christopher I Jones,&nbsp;Stephen Bremner,&nbsp;Jennifer Whetham,&nbsp;Marie Wittevrongel,&nbsp;Ludwig Apers","doi":"10.1080/17843286.2021.2004697","DOIUrl":"https://doi.org/10.1080/17843286.2021.2004697","url":null,"abstract":"The life-expectancy of people living with HIV (PLHIV) has increased due to the earlier and increased use of antiretroviral drugs (ARVs) [1]. The life-expectancy of PLHIV now approximates that of people not living with HIV [2]. Increased life-expectancy will increase the number of PLHIV including those aged 50 years or older [3]. NonHIV cancers, cardiovascular disease, and other noncommunicable diseases (NCDs) are the most common comorbidities in older PLHIV and the most common cause of death of PLHIV in high-income countries. These NCDs also are becoming more prevalent in lowand middle-income countries [4,5] and PLHIV will increasingly need to use HIV and non-HIV health and social services. As part of their HIV-response, many countries are monitoring and evaluating the use, cost, outcome and impact of health services for PLHIV and tracking them across sites [6], which can assist in developing more integrated and cost-effective health services [7]. Mobile Health (mHealth), or the use of wireless technology to deliver health services and information using mobile communication devices, such as mobile phones or other devices [8,9], plays an important role in linking and integrating health services. An increased use of mHealth has been seen in Belgium [10], the United States [11] and other countries as part of their respective responses to their 2020 COVID-19 epidemic. mHealth provides an increasingly important role to ensure continuity of medical and paramedical care in countries, including the management of acute and chronic diseases, such as cancer services [12]. The published studies on mHealth interventions, however, indicate the variable effectiveness of mHealth tools, for those that were HIV-specific [8,9,13] or mHealth tools for other chronic diseases [14,15]. Most of these studies were performed in high-income countries; however, mHealth is increasingly being used in lowand middle-income countries [16–21]. The Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and innovation to Generate Evidence for personalised care (EmERGE) Project co-designed, developed and implemented a new digital mHealth Pathway, including a mobile health application (App) [22]. This allowed for the electronic transfer of personal health information to people living with medically stable HIV and communication with their caregivers [12]. A recent review identified nine functions that an mHealth App ought to fulfil [9]. These functions covered many of the communication aspects, but two important aspects were missing: firstly, that data collected, transmitted, and stored at either end are protected in terms of their confidentiality and security (Table 1); secondly such technology needs to be affordable and efficient [23]. Most studies to date have not included the cost for developing, implementing, and supporting these mHealth Apps, let alone assess their cost-effectiveness or potential cost-savings that mHealth potentially pro","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39642208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination. 辉瑞/BioNTech公司接种SARS-CoV-2疫苗后的无菌性脑膜炎。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-12-01 Epub Date: 2021-12-09 DOI: 10.1080/17843286.2021.2015101
Valérie Dupon, Stijn Arnaert, Eline Van Haute, Friedel Vulsteke, Günter Diet, Gert De Schoenmakere
ABSTRACT Objective Aseptic meningitis is a rare, but possible severe side effect after SARS-CoV-2 Pfizer/BioNTech vaccination. Case Presentation Recently, a first case of aseptic meningitis after the first shot of mRNA-BNT162b2 SARS-CoV-2 (Pfizer/BioNTech) vaccine was reported. We present the first case of a 34-year-old woman without relevant medical history developing aseptic meningitis after her 2nd Pfizer/BioNTech vaccination. She was admitted with severe headache and fever for 5 days prior to her presentation at the emergency department. An extensive work-up of the clinical problem could narrow the differential diagnosis. Symptoms resolved after methylprednisolone therapy. Conclusion This case highlights a rare but important side effect after vaccination that primary physicians and neurologists should be aware of in order to identify and efficiently manage these patients.
目的:无菌性脑膜炎是辉瑞/BioNTech公司接种SARS-CoV-2疫苗后罕见但可能出现的严重副作用。病例介绍:最近报道了首例接种mRNA-BNT162b2 SARS-CoV-2(辉瑞/BioNTech)疫苗后发生的无菌性脑膜炎病例。我们报告了一例34岁无相关病史的女性在第二次辉瑞/BioNTech疫苗接种后发生无菌性脑膜炎的病例。她在急诊科就诊前5天因严重头痛和发烧入院。对临床问题进行广泛的检查可以缩小鉴别诊断的范围。甲强的松龙治疗后症状消失。结论:本病例强调了接种疫苗后罕见但重要的副作用,初级医生和神经科医生应该意识到这一点,以便识别和有效地管理这些患者。
{"title":"Aseptic meningitis after SARS-CoV-2 Pfizer/BioNTech vaccination.","authors":"Valérie Dupon,&nbsp;Stijn Arnaert,&nbsp;Eline Van Haute,&nbsp;Friedel Vulsteke,&nbsp;Günter Diet,&nbsp;Gert De Schoenmakere","doi":"10.1080/17843286.2021.2015101","DOIUrl":"https://doi.org/10.1080/17843286.2021.2015101","url":null,"abstract":"ABSTRACT Objective Aseptic meningitis is a rare, but possible severe side effect after SARS-CoV-2 Pfizer/BioNTech vaccination. Case Presentation Recently, a first case of aseptic meningitis after the first shot of mRNA-BNT162b2 SARS-CoV-2 (Pfizer/BioNTech) vaccine was reported. We present the first case of a 34-year-old woman without relevant medical history developing aseptic meningitis after her 2nd Pfizer/BioNTech vaccination. She was admitted with severe headache and fever for 5 days prior to her presentation at the emergency department. An extensive work-up of the clinical problem could narrow the differential diagnosis. Symptoms resolved after methylprednisolone therapy. Conclusion This case highlights a rare but important side effect after vaccination that primary physicians and neurologists should be aware of in order to identify and efficiently manage these patients.","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39705365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Asparaginase-induced pseudohyponatremia, a case-driven working strategy in pediatric patients. 天冬酰胺酶诱导的假性低钠血症,儿科患者病例驱动的工作策略。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-10-01 Epub Date: 2021-10-19 DOI: 10.1080/17843286.2021.1992583
A Evenepoel, P Herroelen, K Lanckmans, J van der Werff Ten Bosch, M Martin, I Weets, A van Dalem

Objectives: When using indirect ion-selective electrode (ISE) methods, hypertriglyceridemia leads to pseudohyponatremia due to water displacement artifacts. Multiple strategies exist to minimize this interference. Our objective was to create a patient-friendly one-tube-fits-all testing setup without compromising the method robustness.

Methods: Four strategies were evaluated in a single patient with hypertriglyceridemia. Additionally, the interchangeability between the Cobas 8000 and ABL Flex was evaluated on samples (n = 2274) with different total protein (TP) concentrations. Finally, a proof-of-concept (n = 40) was performed by re-measuring the routine sample with the ABL90 Flex.

Results: ABL90 flex results and calculated sodium did not suffer from the presence of high triglyceride levels. We did not observe any significant differences between the three groups (P > 0.05) of sample types (arterial vs. venous plasma vs. venous whole blood after mixing up) nor for the analysers (Roche vs. ABL90 Flex). Passing-Bablok and Bland-Altman tests revealed interchangeability.

Conclusion: In future cases of hypertriglyceridemia, 1500 mg/dL will be used as a preliminary threshold for reliable sodium determination. Routine Li-heparin samples can be used for accurate sodium determination without any need for extra arterial or venous blood gas tubes, offering a patient-friendly test setup for similar cases.

目的:当使用间接离子选择电极(ISE)方法时,由于水置换伪像,高甘油三酯血症导致假性低钠血症。存在多种策略来最小化这种干扰。我们的目标是在不影响方法稳健性的情况下,创建一个对患者友好的一管通的测试设置。方法:对1例高甘油三酯血症患者的4种治疗策略进行评估。此外,在不同总蛋白(TP)浓度的样品(n = 2274)上,对Cobas 8000和ABL Flex的互换性进行了评估。最后,通过使用ABL90 Flex重新测量常规样本进行概念验证(n = 40)。结果:ABL90 flex结果和计算的钠没有受到高甘油三酯水平的影响。我们没有观察到三组样品类型(混合后动脉血浆、静脉血浆、静脉全血)和分析仪(罗氏与ABL90 Flex)之间有任何显著差异(P > 0.05)。passingbablok和Bland-Altman测试揭示了互换性。结论:在未来的高甘油三酯血症病例中,1500mg /dL将作为可靠的钠测定的初步阈值。常规li -肝素样品可用于准确的钠测定,而无需额外的动脉或静脉血气管,为类似病例提供了患者友好的测试设置。
{"title":"Asparaginase-induced pseudohyponatremia, a case-driven working strategy in pediatric patients.","authors":"A Evenepoel,&nbsp;P Herroelen,&nbsp;K Lanckmans,&nbsp;J van der Werff Ten Bosch,&nbsp;M Martin,&nbsp;I Weets,&nbsp;A van Dalem","doi":"10.1080/17843286.2021.1992583","DOIUrl":"https://doi.org/10.1080/17843286.2021.1992583","url":null,"abstract":"<p><strong>Objectives: </strong>When using indirect ion-selective electrode (ISE) methods, hypertriglyceridemia leads to pseudohyponatremia due to water displacement artifacts. Multiple strategies exist to minimize this interference. Our objective was to create a patient-friendly one-tube-fits-all testing setup without compromising the method robustness.</p><p><strong>Methods: </strong>Four strategies were evaluated in a single patient with hypertriglyceridemia. Additionally, the interchangeability between the Cobas 8000 and ABL Flex was evaluated on samples (n = 2274) with different total protein (TP) concentrations. Finally, a proof-of-concept (n = 40) was performed by re-measuring the routine sample with the ABL90 Flex.</p><p><strong>Results: </strong>ABL90 flex results and calculated sodium did not suffer from the presence of high triglyceride levels. We did not observe any significant differences between the three groups (P > 0.05) of sample types (arterial vs. venous plasma vs. venous whole blood after mixing up) nor for the analysers (Roche vs. ABL90 Flex). Passing-Bablok and Bland-Altman tests revealed interchangeability.</p><p><strong>Conclusion: </strong>In future cases of hypertriglyceridemia, 1500 mg/dL will be used as a preliminary threshold for reliable sodium determination. Routine Li-heparin samples can be used for accurate sodium determination without any need for extra arterial or venous blood gas tubes, offering a patient-friendly test setup for similar cases.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39531939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antimicrobial prescription in severe COVID-19 and CAP: a matched case-control study. 重症COVID-19和CAP的抗菌处方:一项匹配的病例对照研究
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-10-01 Epub Date: 2021-10-28 DOI: 10.1080/17843286.2021.1996068
J Fierens, L De Bus, K Colpaert, J Boelens, B Gadeyne, J Decruyenaere, E Van Braeckel, P Depuydt

Background: In severe coronavirus diseases 2019 (COVID-19), a high and potentially excessive use of antimicrobials for suspected bacterial co-infection and intensive care unit (ICU)-acquired infections has been repeatedly reported.

Objectives: To compare an ICU cohort of community-acquired pneumonia (CAP) with a cohort of severe COVID-19 pertaining to co-infections, ICU-acquired infections and associated antimicrobial consumption.

Methods: We retrospectively compared a cohort of CAP patients with a cohort of COVID-19 patients matched according to organ failure, ICU length of stay (LOS) and ventilation days. Patient data such as demographics, infection focus, probability and severity, ICU severity scores and ICU and in-hospital mortality, days of antimicrobial therapy (DOT) and number of antimicrobial prescriptions, using an incremental scale, were registered and analysed. The total number of cultures (sputum, urinary, blood cultures) was collected and corrected for ICU LOS.

Findings: CAP patients (n = 148) were matched to COVID-19 patients (n = 74). Significantly less sputum cultures (68.2% versus 18.9%, P < 0.05) and bronchoalveolar lavages (BAL) (73.7% versus 36.5%, P < 0.05) were performed in COVID-19 patients. Six (8.1%) COVID-19 patients were diagnosed with a co-infection. Respectively, 58 of 148 (39.2%) CAP and 38 of 74 (51.4%) COVID-19 patients (P = 0.09) developed ICU-acquired infections. Antimicrobial distribution, both in the number of prescriptions and DOT, was similar in both cohorts.

Conclusions: We found a low rate of microbiologically confirmed bacterial co-infection and a high rate of ICU-acquired infections in COVID-19 patients. Infection probabilities, antimicrobial prescriptions and DOT were comparable with a matched CAP cohort.

背景:在2019年严重冠状病毒病(COVID-19)中,多次报道了因疑似细菌合并感染和重症监护病房(ICU)获得性感染而大量且可能过度使用抗菌药物的情况。目的:比较社区获得性肺炎(CAP) ICU队列与重症COVID-19队列的合并感染、ICU获得性感染和相关抗菌药物使用情况。方法:回顾性比较CAP患者队列与根据器官衰竭、ICU住院时间(LOS)和通气天数匹配的COVID-19患者队列。患者数据,如人口统计学、感染焦点、概率和严重程度、ICU严重程度评分、ICU和住院死亡率、抗菌药物治疗天数(DOT)和抗菌药物处方数量,使用增量量表进行登记和分析。收集培养总数(痰、尿、血)并校正ICU LOS。结果:CAP患者(n = 148)与COVID-19患者(n = 74)匹配。结论:我们发现COVID-19患者微生物学证实的细菌合并感染率低,icu获得性感染率高。感染概率、抗菌药物处方和DOT与匹配的CAP队列相当。
{"title":"Antimicrobial prescription in severe COVID-19 and CAP: a matched case-control study.","authors":"J Fierens,&nbsp;L De Bus,&nbsp;K Colpaert,&nbsp;J Boelens,&nbsp;B Gadeyne,&nbsp;J Decruyenaere,&nbsp;E Van Braeckel,&nbsp;P Depuydt","doi":"10.1080/17843286.2021.1996068","DOIUrl":"https://doi.org/10.1080/17843286.2021.1996068","url":null,"abstract":"<p><strong>Background: </strong>In severe coronavirus diseases 2019 (COVID-19), a high and potentially excessive use of antimicrobials for suspected bacterial co-infection and intensive care unit (ICU)-acquired infections has been repeatedly reported.</p><p><strong>Objectives: </strong>To compare an ICU cohort of community-acquired pneumonia (CAP) with a cohort of severe COVID-19 pertaining to co-infections, ICU-acquired infections and associated antimicrobial consumption.</p><p><strong>Methods: </strong>We retrospectively compared a cohort of CAP patients with a cohort of COVID-19 patients matched according to organ failure, ICU length of stay (LOS) and ventilation days. Patient data such as demographics, infection focus, probability and severity, ICU severity scores and ICU and in-hospital mortality, days of antimicrobial therapy (DOT) and number of antimicrobial prescriptions, using an incremental scale, were registered and analysed. The total number of cultures (sputum, urinary, blood cultures) was collected and corrected for ICU LOS.</p><p><strong>Findings: </strong>CAP patients (n = 148) were matched to COVID-19 patients (n = 74). Significantly less sputum cultures (68.2% versus 18.9%, P < 0.05) and bronchoalveolar lavages (BAL) (73.7% versus 36.5%, P < 0.05) were performed in COVID-19 patients. Six (8.1%) COVID-19 patients were diagnosed with a co-infection. Respectively, 58 of 148 (39.2%) CAP and 38 of 74 (51.4%) COVID-19 patients (P = 0.09) developed ICU-acquired infections. Antimicrobial distribution, both in the number of prescriptions and DOT, was similar in both cohorts.</p><p><strong>Conclusions: </strong>We found a low rate of microbiologically confirmed bacterial co-infection and a high rate of ICU-acquired infections in COVID-19 patients. Infection probabilities, antimicrobial prescriptions and DOT were comparable with a matched CAP cohort.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39566032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
On the protein content of kidney stones: an explorative study. 关于肾结石蛋白质含量的探索性研究。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-10-01 Epub Date: 2021-11-06 DOI: 10.1080/17843286.2021.1999569
Mieke Steenbeke, Marc L De Buyzere, Marijn M Speeckaert, Joris R Delanghe

Objectives: Kidney stone formation is complex; urinary protein inhibitors play a major role in natural defense against stone formation. Using attenuated total-reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy of kidney stones, proteins are usually not quantified and often reported as 'organic matrix', for which there is little attention: treatment of urolithiasis is based on the nature of the major organic/inorganic stone compound. Literature no longer regards urinary proteins as innocent bystander, but highlights the role of proteins as urolithiasis modulators. We explored the potential significance of the protein content of kidney stones.

Methods: 800 stones were analyzed using ATR-FTIR spectroscopy; spectra were corrected for protein content. The ratio of the amide I peak (1655 cm-1) divided by the maximum peak was calculated. A subgroup of stones (n = 43) was weighed; protein concentration was assayed. Kidney stone composition was taken into account when calculating protein concentration. Electrophoresis was implemented to investigate the protein bands. Multiple regression analysis was carried out to study the influence of various demographic variables (age, gender, stone type) on protein concentration.

Results: Protein concentration showed a marked variation according to the stone composition. High relative protein content (>0.4% stone mass) was found in mixed calcium apatite/calcium oxalate dihydrate stones, mixed calcium oxalate dihydrate/calcium oxalate monohydrate/calcium apatite stones, and mixed calcium oxalate monohydrate/brushite stones, whereas lower protein percentages were found in cystine, urate, and calcium oxalate monohydrate stones. Protein concentration was dependent of the patient's age.

Conclusion: ATR-FTIR is a practical way for assessing protein concentration in kidney stones.

List of abbreviations: A: absorbance; as, asymmetric vibrations; ATR-FTIR, attenuated total-reflectance Fourier-transform infrared; β, standardized regression coefficient; CAP, calcium apatite; COD, calcium oxalate dihydrate; COM, calcium oxalate monohydrate; CV, coefficient of variation; δ, bending vibrations; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; IR, infrared; LOD, limit of detection; LOQ, limit of quantification; MIR, mid-infrared; N or n, amount; r, correlation; r2, coefficient of determination; s, symmetric vibrations; SD, standard deviation; SE, standard error; THP, Tamm-Horsfall protein; UA, uric acid; V, stretching vibrations; VIF: variance inflation factor; ZnSe, zinc selenide.

目的:肾结石形成复杂;尿蛋白抑制剂在自然防御结石形成中起主要作用。使用肾结石的衰减全反射傅立叶变换红外(ATR-FTIR)光谱,蛋白质通常不能被量化,通常被报道为“有机基质”,对此很少引起注意:尿石症的治疗是基于主要有机/无机结石化合物的性质。文献不再将尿蛋白视为无辜的旁观者,而是强调了蛋白质作为尿石症调节剂的作用。我们探讨了肾结石蛋白质含量的潜在意义。方法:采用ATR-FTIR光谱法对800颗结石进行分析;对光谱进行蛋白质含量校正。计算酰胺I峰(1655 cm-1)与最大峰的比值。一组结石(n = 43)称重;测定蛋白浓度。计算蛋白质浓度时考虑肾结石组成。电泳检测蛋白条带。采用多元回归分析研究不同人口统计学变量(年龄、性别、结石类型)对蛋白质浓度的影响。结果:蛋白质浓度随结石组成的不同而有显著差异。混合磷灰石钙/二水合草酸钙结石、混合草酸钙/一水草酸钙/磷灰石钙结石和混合草酸钙/毛石结石的相对蛋白质含量较高(>0.4%),而胱氨酸、尿酸盐和一水草酸钙结石的相对蛋白质含量较低。蛋白质浓度与患者年龄有关。结论:ATR-FTIR是评估肾结石蛋白浓度的实用方法。缩略语列表:A: absorbance;为不对称振动;ATR-FTIR,衰减全反射傅立叶变换红外;β,标准化回归系数;CAP:磷灰石钙;COD,二水合草酸钙;COM,一水草酸钙;CV:变异系数;δ,弯曲振动;ELISA,酶联免疫吸附试验;IQR,四分位间距;红外光谱、红外;LOD,检测限;LOQ,定量限;米尔,中红外;N或N,量;r,相关性;R2,决定系数;S,对称振动;SD:标准差;SE,标准误差;THP, Tamm-Horsfall蛋白;UA,尿酸;V,伸缩振动;VIF:方差膨胀系数;ZnSe,硒化锌。
{"title":"On the protein content of kidney stones: an explorative study.","authors":"Mieke Steenbeke,&nbsp;Marc L De Buyzere,&nbsp;Marijn M Speeckaert,&nbsp;Joris R Delanghe","doi":"10.1080/17843286.2021.1999569","DOIUrl":"https://doi.org/10.1080/17843286.2021.1999569","url":null,"abstract":"<p><strong>Objectives: </strong>Kidney stone formation is complex; urinary protein inhibitors play a major role in natural defense against stone formation. Using attenuated total-reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy of kidney stones, proteins are usually not quantified and often reported as 'organic matrix', for which there is little attention: treatment of urolithiasis is based on the nature of the major organic/inorganic stone compound. Literature no longer regards urinary proteins as innocent bystander, but highlights the role of proteins as urolithiasis modulators. We explored the potential significance of the protein content of kidney stones.</p><p><strong>Methods: </strong>800 stones were analyzed using ATR-FTIR spectroscopy; spectra were corrected for protein content. The ratio of the amide I peak (1655 cm<sup>-1</sup>) divided by the maximum peak was calculated. A subgroup of stones (n = 43) was weighed; protein concentration was assayed. Kidney stone composition was taken into account when calculating protein concentration. Electrophoresis was implemented to investigate the protein bands. Multiple regression analysis was carried out to study the influence of various demographic variables (age, gender, stone type) on protein concentration.</p><p><strong>Results: </strong>Protein concentration showed a marked variation according to the stone composition. High relative protein content (>0.4% stone mass) was found in mixed calcium apatite/calcium oxalate dihydrate stones, mixed calcium oxalate dihydrate/calcium oxalate monohydrate/calcium apatite stones, and mixed calcium oxalate monohydrate/brushite stones, whereas lower protein percentages were found in cystine, urate, and calcium oxalate monohydrate stones. Protein concentration was dependent of the patient's age.</p><p><strong>Conclusion: </strong>ATR-FTIR is a practical way for assessing protein concentration in kidney stones.</p><p><strong>List of abbreviations: </strong>A: absorbance; as, asymmetric vibrations; ATR-FTIR, attenuated total-reflectance Fourier-transform infrared; β, standardized regression coefficient; CAP, calcium apatite; COD, calcium oxalate dihydrate; COM, calcium oxalate monohydrate; CV, coefficient of variation; δ, bending vibrations; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; IR, infrared; LOD, limit of detection; LOQ, limit of quantification; MIR, mid-infrared; N or n, amount; r, correlation; r<sup>2</sup>, coefficient of determination; s, symmetric vibrations; SD, standard deviation; SE, standard error; THP, Tamm-Horsfall protein; UA, uric acid; V, stretching vibrations; VIF: variance inflation factor; ZnSe, zinc selenide.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39596455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national study. 直肠神经内分泌肿瘤病理报告质量和指南依从性:比利时国家研究。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-10-01 Epub Date: 2021-10-04 DOI: 10.1080/17843286.2021.1985806
Bruno Waked, Filip De Maeyer, Saskia Carton, Cuyle Pieter-Jan, Timon Vandamme, Chris Verslype, Pieter Demetter, Ivan Borbath, Liesbet Van Eycken, Anne Hoorens, Karen Geboes, Nancy Van Damme, Suzane Ribeiro

The incidence of neuroendocrine neoplasms (NEN) in the rectum is rising since the introduction of colonoscopy screening programs. Guidelines, such as the European NeuroEndocrine Tumor Society (ENETS) algorithm, are mainly based on expert opinion. The goal of this nationwide study is to gain a better insight into the evolution in pathology reporting and adherence to the ENETS guidelines in Belgium. In Belgium, all NENs have to be reported to the Belgian Cancer Registry. We thoroughly reviewed all available pathology reports, coded as rectal NEN between 2004 and 2015, and reclassified according to World Health Organisation (WHO) classification 2019. To evaluate the adherence to the ENETS guidelines, population-based cancer registry data were linked with the medical procedures of the Belgian Health Insurance database. A total of 670 rectal NEN were retained and 16% of the cases needed reclassification. Annual incidence between 2004 and 2015 tripled from 0,20 to 0,61 per 100.000 inhabitants. Reporting of Ki67 proliferation index ameliorated most, while reporting of tumor size, lymphovascular and perineural invasion remained disappointing. Endoscopic ultrasound was performed in only 36.6% of the cases, while the mostly recommended mode of treatment (endoscopic/surgical/no resection) was followed in the majority of the cases. Incidence of rectal NEN in Belgium increased throughout the years and quality of pathology reporting improved especially after the WHO classification update in 2010. The growing awareness and knowledge among clinicians and pathologists in the community counters the need for centralization.

直肠神经内分泌肿瘤(NEN)的发病率随着结肠镜检查项目的引入而上升。指南,如欧洲神经内分泌肿瘤学会(ENETS)算法,主要基于专家意见。这项全国性研究的目的是更好地了解比利时病理报告的演变和对ENETS指南的遵守情况。在比利时,所有的NENs都必须向比利时癌症登记处报告。我们彻底审查了2004年至2015年期间编码为直肠NEN的所有可用病理报告,并根据世界卫生组织(WHO) 2019年分类进行了重新分类。为了评估对ENETS指南的遵守情况,将基于人群的癌症登记数据与比利时健康保险数据库的医疗程序联系起来。直肠NEN共保留670例,16%的病例需要重新分类。2004年至2015年期间,年发病率从每10万居民0.20人增至0.61人。Ki67增殖指数的报道改善最多,而肿瘤大小、淋巴血管和神经周围浸润的报道仍然令人失望。仅36.6%的病例行内镜超声检查,而大多数病例采用了最推荐的治疗方式(内镜/手术/不切除)。比利时直肠NEN的发病率多年来一直在增加,病理报告的质量也有所提高,特别是在2010年WHO分类更新之后。社区中临床医生和病理学家日益增长的认识和知识抵消了集中的需要。
{"title":"Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national study.","authors":"Bruno Waked,&nbsp;Filip De Maeyer,&nbsp;Saskia Carton,&nbsp;Cuyle Pieter-Jan,&nbsp;Timon Vandamme,&nbsp;Chris Verslype,&nbsp;Pieter Demetter,&nbsp;Ivan Borbath,&nbsp;Liesbet Van Eycken,&nbsp;Anne Hoorens,&nbsp;Karen Geboes,&nbsp;Nancy Van Damme,&nbsp;Suzane Ribeiro","doi":"10.1080/17843286.2021.1985806","DOIUrl":"https://doi.org/10.1080/17843286.2021.1985806","url":null,"abstract":"<p><p>The incidence of neuroendocrine neoplasms (NEN) in the rectum is rising since the introduction of colonoscopy screening programs. Guidelines, such as the European NeuroEndocrine Tumor Society (ENETS) algorithm, are mainly based on expert opinion. The goal of this nationwide study is to gain a better insight into the evolution in pathology reporting and adherence to the ENETS guidelines in Belgium. In Belgium, all NENs have to be reported to the Belgian Cancer Registry. We thoroughly reviewed all available pathology reports, coded as rectal NEN between 2004 and 2015, and reclassified according to World Health Organisation (WHO) classification 2019. To evaluate the adherence to the ENETS guidelines, population-based cancer registry data were linked with the medical procedures of the Belgian Health Insurance database. A total of 670 rectal NEN were retained and 16% of the cases needed reclassification. Annual incidence between 2004 and 2015 tripled from 0,20 to 0,61 per 100.000 inhabitants. Reporting of Ki67 proliferation index ameliorated most, while reporting of tumor size, lymphovascular and perineural invasion remained disappointing. Endoscopic ultrasound was performed in only 36.6% of the cases, while the mostly recommended mode of treatment (endoscopic/surgical/no resection) was followed in the majority of the cases. Incidence of rectal NEN in Belgium increased throughout the years and quality of pathology reporting improved especially after the WHO classification update in 2010. The growing awareness and knowledge among clinicians and pathologists in the community counters the need for centralization.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39485378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Local immune response as novel disease mechanism underlying abdominal pain in patients with irritable bowel syndrome. 局部免疫反应是肠易激综合征患者腹痛的新发病机制。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-10-01 Epub Date: 2021-10-28 DOI: 10.1080/17843286.2021.1996069
J Aguilera-Lizarraga, M Florens, H Hussein, G Boeckxstaens

Objectives: Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder, with a prevalence of up to 25% of the global population. IBS patients suffer from abnormal abdominal pain, or visceral hypersensitivity (VHS), associated with altered bowel habits in the absence of an organic detectable cause. The pathophysiology of the disease is incompletely understood, but the dysregulation of the brain-gut axis is well established in IBS.

Methods: IBS onset is mainly triggered by infectious gastroenteritis, psychological factors, and dietary factors, but genetic predispositions and intestinal dysbiosis might also play a role. Additionally, immune activation, and particularly chronic mast cell activation, have been shown to underlie the development of abdominal pain in IBS.

Results: By releasing increased levels of mediators, including histamine, mast cells sensitize enteric nociceptors and lead to VHS development. The mechanisms underlying aberrant mast cell activation in IBS are still under investigation, but we recently showed that a local break in oral tolerance to food antigens led to IgE-mediated mast cell activation and food-induced abdominal pain in preclinical models and in IBS patients.

Conclusion: The concept of food-mediated VHS highlights the potential of therapies targeting upstream mechanisms of mast cell sensitization to treat IBS.

目的:肠易激综合征(IBS)是最常见的功能性胃肠道疾病,患病率高达全球人口的25%。IBS患者患有异常腹痛,或内脏过敏(VHS),在没有可检测到的有机原因的情况下,与排便习惯改变有关。该疾病的病理生理学尚不完全清楚,但脑肠轴的失调在IBS中得到了很好的证实。方法:IBS的发病主要由感染性胃肠炎、心理因素和饮食因素引起,但遗传易感性和肠道生态失调也可能起作用。此外,免疫激活,特别是慢性肥大细胞激活,已被证明是IBS腹痛发展的基础。结果:肥大细胞通过释放高水平的介质,包括组胺,使肠道伤害感受器敏感,导致VHS的发展。Â肠易激综合征中肥大细胞异常活化的机制仍在研究中,但我们最近发现,在临床前模型和肠易激综合征患者中,口服对食物抗原耐受的局部中断导致ige介导的肥大细胞活化和食物诱导的腹痛。结论:食物介导的VHS概念强调了针对肥大细胞致敏上游机制治疗IBS的潜力。
{"title":"Local immune response as novel disease mechanism underlying abdominal pain in patients with irritable bowel syndrome.","authors":"J Aguilera-Lizarraga,&nbsp;M Florens,&nbsp;H Hussein,&nbsp;G Boeckxstaens","doi":"10.1080/17843286.2021.1996069","DOIUrl":"https://doi.org/10.1080/17843286.2021.1996069","url":null,"abstract":"<p><strong>Objectives: </strong>Irritable bowel syndrome (IBS) is the most frequently diagnosed functional gastrointestinal disorder, with a prevalence of up to 25% of the global population. IBS patients suffer from abnormal abdominal pain, or visceral hypersensitivity (VHS), associated with altered bowel habits in the absence of an organic detectable cause. The pathophysiology of the disease is incompletely understood, but the dysregulation of the brain-gut axis is well established in IBS.</p><p><strong>Methods: </strong>IBS onset is mainly triggered by infectious gastroenteritis, psychological factors, and dietary factors, but genetic predispositions and intestinal dysbiosis might also play a role. Additionally, immune activation, and particularly chronic mast cell activation, have been shown to underlie the development of abdominal pain in IBS.</p><p><strong>Results: </strong>By releasing increased levels of mediators, including histamine, mast cells sensitize enteric nociceptors and lead to VHS development. The mechanisms underlying aberrant mast cell activation in IBS are still under investigation, but we recently showed that a local break in oral tolerance to food antigens led to IgE-mediated mast cell activation and food-induced abdominal pain in preclinical models and in IBS patients.</p><p><strong>Conclusion: </strong>The concept of food-mediated VHS highlights the potential of therapies targeting upstream mechanisms of mast cell sensitization to treat IBS.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39566030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The implementation of risk minimization measures to prevent teratogenic pregnancy outcomes related to oral retinoid and valproate use in Belgium. 在比利时实施风险最小化措施,以防止与口服类维甲酸和丙戊酸使用相关的致畸性妊娠结局。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2022-10-01 Epub Date: 2021-09-26 DOI: 10.1080/17843286.2021.1983708
Xander Bertels, Els Mehuys, Koen Boussery, Lies Lahousse

Introduction: Both oral retinoid and valproate containing medicines are highly teratogenic. Their use by women of childbearing age is controlled by risk minimization measures (RMMs) introduced by the European Medicine Agency, including the pregnancy prevention programme (PPP). In 2018, the RMMs were revised as previous measures were insufficient to prevent the use of these medicines during pregnancies.

Aim & methods: A cross-sectional survey was conducted among patients, physicians and pharmacists to evaluate the implementation of the revised RMMs in Belgium. The primary outcome was compliance with key aspects of the PPP. Differences in compliance between oral retinoid and valproate stakeholders were investigated. The relationship between potential determinants (population characteristics and RMM usage) and compliance was studied via multiple logistic regression.

Results: A total of 317 eligible patients, physicians and pharmacists participated. The majority of the studied patients fail to comply with the PPP, mainly driven by poor implementation of pregnancy testing. A large number of healthcare providers is unaware of the available educational materials.

Conclusion: It is likely that a substantial part of Belgian women of childbearing age using oral retinoids or valproate insufficiently meet the PPP requirements. We propose to better inform healthcare providers about the mandatory PPPs and available educational materials as well as to support them with the implementation of such programmes to improve the safe use of these teratogenic medicines.

口服类维甲酸和丙戊酸类药物均具有高度致畸性。育龄妇女对这些药物的使用受到欧洲医药管理局(European Medicine Agency)引入的风险最小化措施(RMMs)的控制,包括怀孕预防规划(PPP)。2018年,由于以前的措施不足以防止怀孕期间使用这些药物,对RMMs进行了修订。目的和方法:横断面调查在患者、医生和药剂师中进行,以评估修订后的RMMs在比利时的实施情况。主要结果是PPP的关键方面得到遵守。研究了口服类维生素a和丙戊酸利益相关者依从性的差异。通过多元逻辑回归研究了潜在决定因素(人群特征和RMM使用)与依从性之间的关系。结果:共有317名符合条件的患者、医师和药师参与。大多数患者未能遵守PPP,主要原因是妊娠检测执行不力。许多医疗保健提供者不了解现有的教育材料。结论:可能有相当一部分比利时育龄妇女口服类维生素a或丙戊酸盐不足以满足PPP要求。我们建议更好地告知医疗保健提供者强制性公私伙伴关系和可用的教育材料,并支持他们实施此类计划,以提高这些致畸药物的安全使用。
{"title":"The implementation of risk minimization measures to prevent teratogenic pregnancy outcomes related to oral retinoid and valproate use in Belgium.","authors":"Xander Bertels,&nbsp;Els Mehuys,&nbsp;Koen Boussery,&nbsp;Lies Lahousse","doi":"10.1080/17843286.2021.1983708","DOIUrl":"https://doi.org/10.1080/17843286.2021.1983708","url":null,"abstract":"<p><strong>Introduction: </strong>Both oral retinoid and valproate containing medicines are highly teratogenic. Their use by women of childbearing age is controlled by risk minimization measures (RMMs) introduced by the European Medicine Agency, including the pregnancy prevention programme (PPP). In 2018, the RMMs were revised as previous measures were insufficient to prevent the use of these medicines during pregnancies.</p><p><strong>Aim & methods: </strong>A cross-sectional survey was conducted among patients, physicians and pharmacists to evaluate the implementation of the revised RMMs in Belgium. The primary outcome was compliance with key aspects of the PPP. Differences in compliance between oral retinoid and valproate stakeholders were investigated. The relationship between potential determinants (population characteristics and RMM usage) and compliance was studied via multiple logistic regression.</p><p><strong>Results: </strong>A total of 317 eligible patients, physicians and pharmacists participated. The majority of the studied patients fail to comply with the PPP, mainly driven by poor implementation of pregnancy testing. A large number of healthcare providers is unaware of the available educational materials.</p><p><strong>Conclusion: </strong>It is likely that a substantial part of Belgian women of childbearing age using oral retinoids or valproate insufficiently meet the PPP requirements. We propose to better inform healthcare providers about the mandatory PPPs and available educational materials as well as to support them with the implementation of such programmes to improve the safe use of these teratogenic medicines.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39453611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Acta Clinica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1